// App-Quantinova.ai

EP589 : BCX9930, AN ORAL FACTOR D INHIBITOR, CONTROLS EXTRAVASCULAR HEMOLYSIS AND ALLEVIATES ASSOCIATED SYMPTOMS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA INADEQUATELY CONTROLLED ON C5 INHIBITORS

Researchers

Presenter

  • Austin Kulasekararaj

Principal Investigators

  • Wolfgang Freder

  • Shreyans Gandhi

  • Melanie Cornpropst

  • Sylvia Dobo

  • MK Farmer

  • Deborah Kargl

  • William P Sheridan

  • Morag Griffin

  • Antonio Risitano

Medical Centers

  • King's College Hosptial NHS Foundation Trust, London, United Kingdom

  • BioCryst Pharmaceuticals, Inc.,Durham,United States

  • AORN Moscati,Avellino,Italy

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • Medical University of Vienna, Vienna, Austria

Locations

  • United Kingdom

  • United States

  • Italy

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

Disease

  • Paroxysmal nocturnal hemoglobinuria

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • NCT04330534

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved